7451
document
Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women . We have determined whether oral estrogen reduces the biological effects of growth hormone ( GH ) in GH-deficient ( GHD ) women compared with transdermal estrogen treatment . In two separate studies , eight GHD women randomly received either oral or transdermal estrogen for 8 wk before crossing over to the alternate route of administration . The first study assessed the effects of incremental doses of GH ( 0.5 , 1.0 , 2.0 IU/day for 1 wk each ) on insulin-like growth factor I ( IGF-I ) levels during each estrogen treatment phase . The second study assessed the effects of GH ( 2 IU/day ) on lipid oxidation and on protein metabolism using the whole body leucine turnover technique . Mean IGF-I level was significantly lower during oral estrogen treatment ( P < 0.05 ) and rose dose dependently during GH administration by a lesser magnitude ( P < 0.05 ) compared with transdermal treatment . Postprandial lipid oxidation was significantly lower with oral estrogen treatment , both before ( P < 0.05 ) and during ( P < 0.05 ) GH administration , compared with transdermal treatment . Protein synthesis was lower during oral estrogen both before and during GH administration ( P < 0.05 ) . Oral estrogen antagonizes several of the metabolic actions of GH . It may aggravate body composition abnormalities already present in GHD women and attenuate the beneficial effects of GH therapy . Estrogen replacement in GHD women should be administered by a nonoral route .
7452
Intervention_Pharmacological
Oral estrogen
7453
Intervention_Pharmacological
oral estrogen
7454
Intervention_Pharmacological
transdermal estrogen
7455
Intervention_Pharmacological
oral or transdermal estrogen
7456
Intervention_Pharmacological
estrogen
7457
Intervention_Pharmacological
oral estrogen
7458
Intervention_Pharmacological
transdermal treatment
7459
Intervention_Pharmacological
oral estrogen
7460
Intervention_Pharmacological
estrogen
7461
Intervention_Pharmacological
GH
7462
Intervention_Pharmacological
Oral estrogen
7463
Intervention_Pharmacological
GH therapy
7464
Intervention_Pharmacological
Estrogen replacement
7465
Outcome_Physical
Mean IGF-I level
7466
Outcome_Physical
Postprandial lipid oxidation
7467
Outcome_Physical
Protein synthesis
7468
Outcome_Physical
antagonizes several of the metabolic actions of GH